Evolution of bevacizumab-based therapy in the management of breast cancer

Clinical Breast Cancer

Volumn 8, Issue 5, 2008, Pages 402-410

  Sachdev, Jasgit ^a   Jahanzeb, Mohammad ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Adjuvant chemotherapy; Angiogenesis; Monoclonal antibody; Progression free survival; Vascular endothelial growth factor

Indexed keywords

ALBUMIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IXABEPILONE; LAPATINIB; LETROZOLE; MELPHALAN; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLACEBO; PREDNISONE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ANGIOGENESIS; BLEEDING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL ASSESSMENT; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERANCE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; MULTIPLE CYCLE TREATMENT; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RELAPSE; REVIEW; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR GROWTH; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; MORTALITY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS;

EID: 58149232648     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.n.048     Document Type: Review

References (69)

1. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J Clin Oncol 2003; 21:588-92.
2. Stewart DJ, Evans WK, Shepherd FA, et al. Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin. J Clin Oncol 1997; 15:1897-905.
3. O'Shaughnessy J, Nag S, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): interim results of a global phase III study. Proc Am Soc Clin Oncol 2003; 22:7 (Abstract 25).
4. Albain KS, Nag S, Calderillo RG, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. Proc Am Soc Clin Oncol 2004; 23:4 (Abstract 510).
5. O'Shaughnessy JA, Brufsky AM. RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer. Clin Breast Cancer 2008; 8:370-3.
6. Clinicaltrials.gov [Web site]. Study of Avastin (bevacizumab) in combination with herceptin (trastuzumab)/docetaxel in patients with HER2 positive metastatic breast cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00391092?term =Bo20231&rank= 1
7. Clinicaltrials.gov [Web site]. First-line chemotherapy and trastuzumab with or without bevacizumab in treating patients with metastatic breast cancer that overexpresses HER-2/neu. Available at:
8. Clinicaltrials.gov [Web site]. BEATRICE study: a study of Avastin (bevacizumab) adjuvant therapy in triple negative breast cancer. Available at: http://clinicaltrials. gov/ct2/show/NCT00528567?term=BEATRICE&rank=1
9. Clinicaltrials.gov [Web site]. NSABP B-44-I: BETH study: Treatment of HER2 positive breast cancer with chemotherapy plus trastuzumab vs chemotherapy plus trastuzumab plus bevacizumab. Available at: http://clinicaltrials.gov/ct2/show/NC T00625898?term=BETH%3B+NSABP&rank=1
10. Clinicaltrials.gov [Web site]. Chemotherapy with or without bevacizumab in treating women with stage I, stage II, or stage IIIa breast cancer that can be removed by surgery. Available at: http://clinicaltrials.gov/ct2/show/ NCT00408408?term=NSABP+B-40&rank= 1
11. Clinicaltrials.gov [Web site]. Doxorubicin, cyclophosphamide, and paclitaxel with or without bevacizumab in treating patients with lymph node-positive or highrisk, lymph node-negative breast cancer. Available at: http://clinicaltrials.gov/ct2/ show/NCT00433511?term=e5103&rank=1
12. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007; 356:1670-4.
13. Ravdin PM, Cronin KA, Howlader N, et al. Major changes in breast cancer incidence in the United States over the period 2002 to 2004. J Clin Oncol 2007; 25(18 suppl):69s (Abstract 1533).
14. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
15. Cardoso F, Di LA, Lohrisch C. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades. Ann Oncol 2002; 13:197-207.
16. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005; 10(suppl 3):20-9.
17. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794-803.
18. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92.
19. Engelsman E, Klijn JC, Rubens RD, et al. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). Eur J Cancer 1991; 27:966-70.
20. Bontenbal M, Creemers GJ, Braun HJ, et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 2005; 23:7081-8.
21. Jassem J, Pienkowski T, Pluzåska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001; 19:1707-15.
22. Pegram M, Chan D, Dichmann RA, et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Res Treat 2006; 100(suppl 1):21 (Abstract 301).
23. Moore A. Breast-cancer therapyâ"looking back to the future. N Engl J Med 2007; 357:1547-9.
24. Miller KD, O'Neil A, Perez EA, et al. Phase II feasibility trial incorporating bevacizumab into dose dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial of the Eastern Cooperative Oncology Group (E2104). Presented at: the 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, TX. Abstract 3063.
25. Mcarthur HL, Rugo H, Paulson M, et al. Cardiac safety of adjuvant bevacizumab plus dose-dense doxorubicin/cyclophosphamide followed by nanoparticle albumin-bound paclitaxel in patients with early stage breast cancer. Presented at: the 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, TX. Abstract 3065.
26. Sledge G, Miller K, Moisa C, et al. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. J Clin Oncol 2007; 25(18 suppl):35s (Abstract 1013).
27. Ramaswamy B, Elias AD, Kelbick NT, et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 2006; 12:3124-9.
28. Perez EA, Hillman DW, Kugler JW, et al. North Central cancer treatment group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first line chemotherapy for patients with metastatic breast cancer. Presented at: the 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX. Abstract 2069.
29. Conlin AK, Seidman AD, Moynahan ME, et al. Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: an initial interim safety report. J Clin Oncol 2007; 25(18 suppl):58s (Abstract 1104).
30. Traina TA, Rugo H, Caravelli J, et al. Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). J Clin Oncol 2006; 24(18 suppl):133s (Abstract 3050).
31. Dickler M, Rugo H, Caravelli J, et al. Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2004; 23:127 (Abstract 2001).
32. Grothey A, Sugrue M, Hedrick E, et al. Association between exposure to Bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE). J Clin Oncol 2007; 25(18 suppl)172s (Abstract 4036).
33. Yen L, You XL, Al Moustafa AE, et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000; 19:3460-9.
34. Konecny GE, Meng YG, Untch M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004; 10:1706-16.
35. Bishop JF, Dewar J, Toner GC, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999; 17:2355-64.
36. Seidman AD, Berry D, Cirrincione C, et al. CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc Am Soc Clin Oncol 2004; 23:6 (Abstract 512).
37. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-23.
38. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999; 17:1413-24.
39. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23:5542-51.
40. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733-43.
41. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracyclines and taxane treatment. J Clin Oncol 2007; 25:5210-7.
42. Jones S, Winer E, Vogel C, et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995; 13:2567-74.
43. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17:2341-54.
44. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
45. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-6.
46. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84:1875-87.
47. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-76.
48. Folkman J. Antiangiogenesis agents. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:2865-82.
49. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57:963-9.
50. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995; 26:86-91.
51. Pavlakis K, Messini I, Vrekoussis T, et al. The assessment of angiogenesis and fibroblastic stromagenesis in hyperplastic and pre-invasive breast lesions. BMC Cancer 2008; 8:88.
52. Toi M, Inada K, Suzuki H, et al. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 1995; 36:193-204.
53. Gasparini G, Toi M, Miceli R, et al. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J Sci Am 1999; 5:101-11.
54. Avastinâ® (bevacizumab) [package insert]. South San Francisco: Genentech, Inc; 2008.
55. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391-400.
56. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
57. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50.
58. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-7.
59. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005; 15:102-11.
60. Wildiers H, Guetens G, De Boeck G, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003; 88:1979-86.
61. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165:35-52.
62. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30 (5 suppl 16):117-24.
63. Lu JF, Bruno R, Eppler S, et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008; 62:779-86.
64. Cassidy J, Clarke S, Dãaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26:2006-12.
65. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792-9.
66. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-76.
67. Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. Presented at: the American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2008; Chicago, IL. Abstract LBA1011.
68. Clinicaltrials.gov [Web site]. A study of Avastin (bevacizumab) plus taxane-based therapy in patients with locally recurrent or metastatic breast cancer. Available at: http:// clinicaltrials.gov/ct2/show/NCT00448591?term=MO19391&rank=1
69. Clinicaltrials.gov [Web site]. Tamoxifen or letrozole with or without bevacizumab in treating women with stage III or stage IV breast cancer. Available at: http://clinicaltrials. gov/ct2/show/NCT00601900?term=CALGB+40503&rank=1